Zealand Pharma A/S (LON:0NZU)

Market Cap	3.31B -46.7%
Revenue (ttm)	1.07B +11,809.7%
Net Income	764.70M
EPS	10.71
Shares Out	n/a
PE Ratio	4.33
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,234
Average Volume	14,908
Open	417.50
Previous Close	420.25
Day's Range	403.40 - 416.00
52-Week Range	307.10 - 786.50
Beta	0.56
RSI	41.34
Earnings Date	Feb 19, 2026

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 440
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NZU

Financial Performance

In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.

Financial numbers in DKK